Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Ascierto, Paolo A, Dr, Del Vecchio, Michele, MD, Robert, Caroline, Prof, Mackiewicz, Andrzej, Prof, Chiarion-Sileni, Vanna, MD, Arance, Ana, MD, Lebbé, Céleste, Prof, Bastholt, Lars, MD, Hamid, Omid, MD, Rutkowski, Piotr, Prof, McNeil, Catriona, MD, Garbe, Claus, Prof, Loquai, Carmen, MD, Dreno, Brigitte, Prof, Thomas, Luc, Prof, Grob, Jean-Jacques, Prof, Liszkay, Gabriella, Prof, Nyakas, Marta, MD, Gutzmer, Ralf, Prof, Pikiel, Joanna, MD, Grange, Florent, MD, Hoeller, Christoph, MD, Ferraresi, Virginia, MD, Smylie, Michael, MD, Schadendorf, Dirk, Prof, Mortier, Laurent, Prof, Svane, Inge Marie, MD, Hennicken, Delphine, MSc, Qureshi, Anila, MD, Maio, Michele, MD
Published in The lancet oncology (01.05.2017)
Published in The lancet oncology (01.05.2017)
Get full text
Journal Article
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof
Published in The lancet oncology (01.09.2019)
Published in The lancet oncology (01.09.2019)
Get full text
Journal Article